ATE435855T1 - Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor - Google Patents

Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor

Info

Publication number
ATE435855T1
ATE435855T1 AT04811663T AT04811663T ATE435855T1 AT E435855 T1 ATE435855 T1 AT E435855T1 AT 04811663 T AT04811663 T AT 04811663T AT 04811663 T AT04811663 T AT 04811663T AT E435855 T1 ATE435855 T1 AT E435855T1
Authority
AT
Austria
Prior art keywords
compounds
receptor
beta2
agonistic action
muscarinic
Prior art date
Application number
AT04811663T
Other languages
English (en)
Inventor
Mathai Mammen
Sarah Dunham
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE435855T1 publication Critical patent/ATE435855T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Document Processing Apparatus (AREA)
  • Hydrogenated Pyridines (AREA)
AT04811663T 2003-11-21 2004-11-19 Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor ATE435855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52423403P 2003-11-21 2003-11-21
PCT/US2004/038975 WO2005051946A2 (en) 2003-11-21 2004-11-19 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Publications (1)

Publication Number Publication Date
ATE435855T1 true ATE435855T1 (de) 2009-07-15

Family

ID=34632881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04811663T ATE435855T1 (de) 2003-11-21 2004-11-19 Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor

Country Status (9)

Country Link
US (4) US7345060B2 (de)
EP (1) EP1685118B1 (de)
JP (2) JP4851937B2 (de)
CN (1) CN100569760C (de)
AT (1) ATE435855T1 (de)
CA (1) CA2543858C (de)
DE (1) DE602004021959D1 (de)
ES (1) ES2329586T3 (de)
WO (1) WO2005051946A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28417A1 (es) * 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
AR048573A1 (es) * 2003-07-17 2006-05-10 Glaxo Group Ltd Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
SI1677795T1 (sl) * 2003-10-14 2011-04-29 Glaxo Group Ltd Antagonisti muskarinskega acetilholinskega receptorja
EP1677796A4 (de) * 2003-10-17 2006-12-27 Glaxo Group Ltd Muskarinische acetylcholin-rezeptorantagonisten
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
EP1723110A1 (de) 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087733A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7262205B2 (en) 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (de) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonisten des muscarinischen acetylcholinrezeptors
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7629336B2 (en) * 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1866284A1 (de) * 2005-03-10 2007-12-19 Theravance, Inc. Biphenylverbindungen als muskarinrezeptorantagonisten
US7728144B2 (en) 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
US20080234315A1 (en) * 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CA2758353C (en) * 2009-04-14 2017-06-06 Dean David Edney Process for the preparation of a biphenyl-2-ylcarbamic acid ester
AU2010253770B9 (en) * 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
GB0913342D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
JP5959117B2 (ja) 2010-07-13 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ビフェニル−２−イルカルバミン酸を調製するためのプロセス
WO2012032546A2 (en) * 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
HRP20151317T1 (hr) 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
EP3345904B1 (de) 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Verbindungen mit muskarinrezeptorantagonisten- und beta2-adrenergen-rezeptoragonistenaktivität
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
CN107849019A (zh) * 2016-01-22 2018-03-27 四川海思科制药有限公司 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
EP3484879B1 (de) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxychinolinonverbindungen mit muskarinrezeptorantagonisten- und beta2-adrenergenrezeptoragonistenaktivität
JP6963616B2 (ja) 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
TW201907922A (zh) * 2017-07-21 2019-03-01 大陸商四川海思科製藥有限公司 氮雜環醯胺衍生物之組合物及其製備方法
WO2019015640A1 (zh) * 2017-07-21 2019-01-24 四川海思科制药有限公司 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
CN115093365B (zh) * 2022-07-25 2023-07-25 沈阳药科大学 一种雷芬那辛的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181802A (en) * 1978-05-11 1980-01-01 Janssen Pharmaceutica N.V. 1-(Heterocyclylalkyl)-1,3-dihydro-2-H-benzimidazole-2-ones
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
GB9211172D0 (en) 1992-05-27 1992-07-08 Fisons Plc Compounds
US5648370A (en) 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
GB9210632D0 (en) 1992-05-19 1992-07-01 Fisons Plc Compounds
IE914003A1 (en) 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
PT640081E (pt) 1992-03-31 2000-05-31 Glaxo Group Ltd Derivados de fenil-carbamatos e fenil-ureias substituidos sua preparacao e sua utilizacao como antagonistas 5-ht4
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
TW356468B (en) 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
DE69615214T2 (de) 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate
GB9526511D0 (en) 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
EP1047691A1 (de) 1997-12-12 2000-11-02 Smithkline Beecham Plc Chinolinpiperazin- und chinolinpiperidin derivate, deren herstellung und deren verwendung als kombinierte 5-ht1a, 5-ht1b und 5-ht1d rezeptor antagonisten
JP2002517464A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド ムスカリン性レセプターアンタゴニスト
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
SE9900693D0 (sv) 1999-02-26 1999-02-26 Astra Pharma Prod Novel process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902937D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902938D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902936D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7094790B2 (en) * 2003-05-07 2006-08-22 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.

Also Published As

Publication number Publication date
US7838535B2 (en) 2010-11-23
US7345060B2 (en) 2008-03-18
EP1685118B1 (de) 2009-07-08
US20110034694A1 (en) 2011-02-10
US20080096911A1 (en) 2008-04-24
US7842704B2 (en) 2010-11-30
WO2005051946A2 (en) 2005-06-09
JP4851937B2 (ja) 2012-01-11
US20080097105A1 (en) 2008-04-24
ES2329586T3 (es) 2009-11-27
JP2007514662A (ja) 2007-06-07
CN100569760C (zh) 2009-12-16
WO2005051946A3 (en) 2005-07-14
US20050113417A1 (en) 2005-05-26
CA2543858C (en) 2014-04-15
CN1882556A (zh) 2006-12-20
CA2543858A1 (en) 2005-06-09
JP2011190271A (ja) 2011-09-29
EP1685118A2 (de) 2006-08-02
US8247564B2 (en) 2012-08-21
DE602004021959D1 (de) 2009-08-20

Similar Documents

Publication Publication Date Title
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
DE602004024375D1 (de) Carboxamidderivate
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
CY1111693T1 (el) Αντιιικοι παραγοντες
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
IL177962A0 (en) Compounds and methods for treating dyslipidemia
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
SE0202133D0 (sv) Novel compounds
EA200702497A1 (ru) Замещенные арилпиразолы для применения против паразитов
ATE466860T1 (de) Cgrp-rezeptorantagonisten
IL176247A0 (en) Cyclopropane compounds and pharmaceutical use thereof
SE0300119D0 (sv) Novel compounds
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
ATE386725T1 (de) Heterocyclylverbindungen
TW200738658A (en) Novel compounds
BRPI0517425A (pt) composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
MY141583A (en) Novel fused heterocycles and uses thereof
SE0303541D0 (sv) New compounds
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
BRPI0519292A2 (pt) compostos orgÂnicos
GEP20084306B (en) Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties